Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts

Although histone deacetylase inhibitors (HDACi) are a promising class of anti-cancer drugs, thus far, they have been unsuccessful in early phase clinical trials for pancreatic ductal adenocarcinoma (PDAC). One potential reason for their poor efficacy is the tumor stroma, where cancer-associated fibr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Andrew H., Elliott, Irmina A., Wu, Nanping, Matsumura, Cynthia, Vogelauer, Maria, Attar, Narsis, Dann, Amanda, Ghukasyan, Razmik, Toste, Paul A., Patel, Sanjeet G., Williams, Jennifer L., Li, Luyi, Dawson, David W., Radu, Caius, Kurdistani, Siavash K., Donahue, Timothy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386671/
https://www.ncbi.nlm.nih.gov/pubmed/27894105
http://dx.doi.org/10.18632/oncotarget.13572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386671/
https://www.ncbi.nlm.nih.gov/pubmed/27894105
http://dx.doi.org/10.18632/oncotarget.13572

Ejemplares similares